Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
breast cancer (BC), lapatinib plus capecitabine vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results EGF100151, 2006 0.81 [0.65; 1.00]
EMILIA, 2012 (REV) 1.47 [1.18; 1.83]
NALA, 2020 (REV) 1.14 [0.93; 1.39]
NALA (brain metastases), 2020 (REV) 1.11 [0.73; 1.70]
1.11 [0.84 ; 1.45 ] EGF100151, 2006, EMILIA, 2012 (REV), NALA, 2020 (REV), NALA (brain metastases), 2020 (REV) 4 80% 2,037 moderate not evaluable deaths (OS) (extension)detailed results EMILIA, 2012 (REV) 1.33 [1.14; 1.56]
1.33 [1.14 ; 1.56 ] EMILIA, 2012 (REV) 1 0% 991 NA not evaluable progression or deaths (PFS)detailed results EMILIA, 2012 (REV) 1.54 [1.30; 1.82]
NALA, 2020 (REV) 1.32 [1.08; 1.60]
NALA (brain metastases), 2020 (REV) 1.52 [0.95; 2.42]
1.44 [1.28 ; 1.63 ] EMILIA, 2012 (REV), NALA, 2020 (REV), NALA (brain metastases), 2020 (REV) 3 0% 1,713 moderate not evaluable DORdetailed results NALA, 2020 (REV) 2.00 [1.34; 2.99]
NALA (brain metastases), 2020 (REV) 2.13 [0.53; 8.51]
2.01 [1.36 ; 2.96 ] NALA, 2020 (REV), NALA (brain metastases), 2020 (REV) 2 0% 722 moderate not evaluable objective responses (ORR)detailed results EGF100151, 2006 1.70 [0.96; 3.03]
EMILIA, 2012 (REV) 0.58 [0.43; 0.77]
NALA (brain metastases), 2020 (REV) 0.98 [0.36; 2.70]
0.96 [0.44 ; 2.10 ] EGF100151, 2006, EMILIA, 2012 (REV), NALA (brain metastases), 2020 (REV) 3 82% 1,184 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results EGF100151, 2006 1.15 [0.59; 2.25]
1.15 [0.59 ; 2.25 ] EGF100151, 2006 1 0% 316 NA not evaluable Anaemia AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 2.06 [0.07; 62.92]
2.06 [0.07 ; 62.92 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Asthenia AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 3.20 [0.32; 31.83]
3.20 [0.32 ; 31.83 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Back pain AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 1.02 [0.02; 52.48]
1.02 [0.02 ; 52.48 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Constipation AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 1.02 [0.02; 52.48]
1.02 [0.02 ; 52.48 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Decreased appetite AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 1.02 [0.06; 16.79]
1.02 [0.06 ; 16.79 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Diarrhoea AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 0.40 [0.13; 1.26]
0.40 [0.13 ; 1.26 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Fatigue AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 1.02 [0.14; 7.55]
1.02 [0.14 ; 7.55 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Headache AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 1.02 [0.02; 52.48]
1.02 [0.02 ; 52.48 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Nausea AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 1.57 [0.25; 9.80]
1.57 [0.25 ; 9.80 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 1.02 [0.31; 3.42]
1.02 [0.31 ; 3.42 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Pyrexia AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 2.06 [0.07; 62.92]
2.06 [0.07 ; 62.92 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Rash AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 2.06 [0.07; 62.92]
2.06 [0.07 ; 62.92 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Stomatitis AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 2.06 [0.07; 62.92]
2.06 [0.07 ; 62.92 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Vomiting AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 1.02 [0.06; 16.79]
1.02 [0.06 ; 16.79 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable Weight decreased AE (grade 3-4)detailed results NALA (brain metastases), 2020 (REV) 1.02 [0.06; 16.79]
1.02 [0.06 ; 16.79 ] NALA (brain metastases), 2020 (REV) 1 0% 99 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-10 19:13 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3
- treatments: 1312
